1. Home
  2. CGBD vs COGT Comparison

CGBD vs COGT Comparison

Compare CGBD & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGBD
  • COGT
  • Stock Information
  • Founded
  • CGBD 2012
  • COGT 2014
  • Country
  • CGBD United States
  • COGT United States
  • Employees
  • CGBD N/A
  • COGT N/A
  • Industry
  • CGBD Finance: Consumer Services
  • COGT Biotechnology: Pharmaceutical Preparations
  • Sector
  • CGBD Finance
  • COGT Health Care
  • Exchange
  • CGBD Nasdaq
  • COGT Nasdaq
  • Market Cap
  • CGBD 1.0B
  • COGT 1.1B
  • IPO Year
  • CGBD 2017
  • COGT 2018
  • Fundamental
  • Price
  • CGBD $13.79
  • COGT $13.05
  • Analyst Decision
  • CGBD Hold
  • COGT Strong Buy
  • Analyst Count
  • CGBD 5
  • COGT 11
  • Target Price
  • CGBD $14.63
  • COGT $21.20
  • AVG Volume (30 Days)
  • CGBD 412.0K
  • COGT 1.3M
  • Earning Date
  • CGBD 11-04-2025
  • COGT 08-05-2025
  • Dividend Yield
  • CGBD 12.33%
  • COGT N/A
  • EPS Growth
  • CGBD N/A
  • COGT N/A
  • EPS
  • CGBD 1.14
  • COGT N/A
  • Revenue
  • CGBD $234,464,000.00
  • COGT N/A
  • Revenue This Year
  • CGBD $14.68
  • COGT N/A
  • Revenue Next Year
  • CGBD $5.53
  • COGT N/A
  • P/E Ratio
  • CGBD $12.05
  • COGT N/A
  • Revenue Growth
  • CGBD N/A
  • COGT N/A
  • 52 Week Low
  • CGBD $13.12
  • COGT $3.72
  • 52 Week High
  • CGBD $18.64
  • COGT $13.50
  • Technical
  • Relative Strength Index (RSI)
  • CGBD 48.78
  • COGT 66.38
  • Support Level
  • CGBD $13.73
  • COGT $11.87
  • Resistance Level
  • CGBD $14.00
  • COGT $13.50
  • Average True Range (ATR)
  • CGBD 0.19
  • COGT 0.55
  • MACD
  • CGBD 0.01
  • COGT 0.05
  • Stochastic Oscillator
  • CGBD 58.12
  • COGT 77.16

About CGBD Carlyle Secured Lending Inc.

Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: